✦ LIBER ✦

Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

✍ Scribed by Francis J. Giles; Paula M. Fracasso; Hagop M. Kantarjian; Jorge E. Cortes; Randy A. Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A. Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P. Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F. DiPersio; Varsha Gandhi

Book ID: 108403296
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 107 KB
Volume: 27
Category: Article
ISSN: 0145-2126
DOI: 10.1016/s0145-2126(03)00118-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of Tri

Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies

✍ Ivana Gojo; Michael L. Tidwell; Jacqueline Greer; Naoko Takebe; Karen Seiter; Ma 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 712 KB

A Phase I study of the novel ribonucleot

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

✍ Judith E. Karp; Francis J. Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB

A phase I study of Triapine®in combinati

A phase I study of Triapine®in combination with doxorubicin in patients with advanced solid tumors

✍ William R. Schelman; Sherry Morgan-Meadows; Rebecca Marnocha; Fred Lee; Jens Eic 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 364 KB

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB

Phase II trial of the ribonucleotide red

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

✍ Allyson J. Ocean; Paul Christos; Joseph A. Sparano; Dan Matulich; Andreas Kaubis 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 273 KB

Phase I and pharmacokinetic study of a l

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

✍ Francis J. Giles; Martin S. Tallman; Guillermo Garcia-Manero; Jorge E. Cortes; D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose